header ADC report 540x680@2x
NICE INSIGHT REPORT

Antibody–Drug Conjugates: 2023 Market Analysis, CDMO Pricing and Benchmarking

Coming August, 2023
  • 30 company profiles for a comprehensive CDMO landscape
  • 100 pages of ADC market insights and breakthroughs
  • 2023 CDMO pricing data for competitive benchmarking
  • ADC manufacturing process and pricing study
  • Market projections on the fast-expanding modality
header ADC report 540x680@2x

Key market insights for innovators, CDMOs and investors in the Antibody–Drug Conjugate industry.

01 analytics icon 65x65@2x

The market trends that decision makers need to know

Our complete Market Analysis uses scientific insights from PhDs and researchers to provide an exhaustive overview of the ADC industry. From the emergence of ADCs as cancer treatments to how big pharma has penetrated ADC, stay ahead of market trends with our report.
02 report icon 65x65@2x

Exclusive pricing data to benchmark against peers

Keep your sales team ahead of the curve by using our primary data for an accurate pricing comparison. Our Market Analysis provides a manufacturing process and strategic pricing study designed to give CDMOs a competitive edge.

Coming August, 2023

Market intelligence for research, manufacturing and pricing all in one report.

The Antibody–Drug Conjugates: 2023 Market Analysis, CDMO Pricing and Benchmarking provides

01 benchmarks icon 65x65@2x
Current pricing data
for benchmarking in the emerging market
02 gears icon 65x65@2x
Manufacturing technologies
that are invaluable for ADC manufacturers
03 insights icon 65x65@2x
Hundreds of pages
of market insights for your sales team
04 research icon 65x65@2x
30 company profiles
of top CDMOs in the U.S., Europe and Asia
05 pipeline icon 65x65@2x
Pipeline overview
and the approval and regulatory landscape
06 complexities icon 65x65@2x
Value-chain analysis
and the unique complexities in ADC production

Over 700 hours of data collection and analysis —
interviews with CDMO owners, KOLs and industry experts

Table of Contents

Executive Summary

Overview of the report

Study Methodology

Section I:

Background on Antibody–Drug Conjugates

  • In the era precision medicine
  • Bio engineering breakthrough
  • New emergence of ADCs as cancer treatments
  • Increasing number of cancer patients and longer life expectancy
  • High needs in non-invasive treatment

Section II:

ADCs Market Overview

  • 1. ADCs Market Growth and Projection
    • - Fast-expanding therapeutic modality
    • - Unique therapeutic value of ADCs
    • - Accelerated penetration of big pharma into ADCs
  • 2. Market opportunities and challenges
  • 3. Approval and development Overview
    • - Approval and regulatory landscape
    • - Preclinical
    • - Phase l
    • - Phase ll
    • - Phase lll
  • 4. Market Segmentation by disease application
    • - Oncological indication
    • - Hematological indication
    • - Non oncological (autoimmune and infectious disease)

Section lll:

ADCs CDMO Market Outlook

  • Market Overview
  • Growth drivers and projections
  • Opportunities and challenges

Section IV:

ADC Manufacturing Technologies

  • Three important components of ADCs
  • Comparison of different ADCs manufacturing technologies
    • - Cleavable and non-cleavable
    • - Linker technology
    • - Linkerless ADCs
  • Analysis on payload technology

Section V:

Unique Considerations and Complexities in ACD Development and Manufacturing

  • Overview of the unique considerations and complexities in ADC development and manufacturing
  • Challenges in developing and manufacturing ADCs
  • Impact of these challenges on the development and manufacturing process

Section VI:

Strategic Pricing Study

  • Manufacturing process
  • Strategic pricing

Section VII:

ADCs CDMOs Profile

  • Regional Analysis
  • Summary of Services and capacities
  • Individual company profiles
ADC report form@2x-1
Coming August, 2023
Request your copy of the 2023 Antibody–Drug Conjugates Report

ADC report form@2x-1